Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma—a prospective study
- 2 September 2003
- journal article
- research article
- Published by Wiley in Head & Neck
- Vol. 25 (10) , 864-872
- https://doi.org/10.1002/hed.10307
Abstract
Background. This study prospectively examines the prognostic role of p53 oncoprotein (p53), Ki67-antigen (Ki67), tumor angiogenesis (MVD), epidermal growth factor receptor (EGFR), and HER2 receptor protein (HER2) expression in Chinese with undifferentiated nasopharyngeal carcinoma (NPC). Methods. Seventy-eight Chinese were recruited from October 1995 to July 1997 at the Prince of Wales Hospital, Hong Kong. Pretreatment immunohistochemical preparations of the primary tumor were made, and clinical data were collected prospectively until October 30, 2000. The markers were correlated with overall survival (OS), disease-free survival (DFS), time to progression (TTP), and UICC stage. Results. On univariate analysis, EGFR expression correlated with poorer OS (p = .0001), DFS (p = .01), shorter TTP (p = .0001), and advanced T stage (p = .036). Strong EGFR expression, when compared with weak or moderate, was associated with poorer OS (p = .04) and shorter TTP in a subgroup of patients with UICC stage III–IV disease. HER2 expression was associated with advanced UICC stage (p = .006). The presence of p53 expression correlated with poorer DFS (p = .01) and a trend toward shorter TTP (p = .06). No correlation was found with Ki67-antigen or MVD. On multivariate analysis, only EGFR expression was significantly linked to shorter OS and TTP. Conclusions. EGFR expression in undifferentiated NPC is associated with a poor clinical outcome. A prognostic role of p53 and HER2 expression is suggestive but not consistently defined in this study. The relatively high prevalence of positive staining for EGFR supports the use of molecular targeted therapy in this disease. © 2003 Wiley Periodicals, Inc. Head and Neck 25: 864–872, 2003Keywords
This publication has 29 references indexed in Scilit:
- Concurrent Chemotherapy-Radiotherapy Compared With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma: Progression-Free Survival Analysis of a Phase III Randomized TrialJournal of Clinical Oncology, 2002
- Anticancer therapy targeting the erbB family of receptor tyrosine kinasesSeminars in Oncology, 2001
- The Relationship Between Microvessel Density, the Expression of Vascular Endothelial Growth Factor (VEGF), and the Extension of Nasopharyngeal CarcinomaThe Laryngoscope, 2000
- p53 Gene Alterations in Prostate Cancer After Radiation Failure and Their Association with Clinical Outcome: A Molecular and Immunohistochemical AnalysisPathology - Research and Practice, 1999
- Epstein‐Barr Virus‐encoded Latent Membrane Protein 1 Co‐expresses with Epidermal Growth Factor Receptor in Nasopharyngeal CarcinomaJapanese Journal of Cancer Research, 1999
- p53 Mutation and Locoregional Treatment Failure in Head and Neck Squamous Cell CarcinomaJNCI Journal of the National Cancer Institute, 1996
- Correlation of epidermal growth factor receptor and c-erbB2 oncogene product to known prognostic indicators of colorectal cancerSurgical Oncology, 1992
- A comparison of epidermal growth factor receptor (EGFR) and c-erbB-2 oncogene expression in head and neck squamous cell carcinomasPathology, 1991
- AMPLIFICATION OF c-erbB-2 ONCOGENE IN HUMAN ADENOCARCINOMAS IN VIVOThe Lancet, 1986